Collection 5 (Sep 2024 - Aug 2025) Articles

Articles
Determinants of lack of atherosclerosis progression in adult patients with elevated lipoprotein (a): results from the STAR-Lp(a) study
Sosnowska B, Bytyci I, Lewek J, et al.
Journal:
Archives of Medical Science

First published: August 31, 2025 DOI: 10.5114/aoms/209946
View
- Share
Articles
Inclisiran-based treatment strategy in hypercholesterolaemia: the VICTORION-Difference trial
Landmesser U, Laufs U, Schatz U, et al.
Journal:
Eur Heart J

First published: August 30, 2025 DOI: 10.1093/eurheartj/ehaf685
View
- Share
Articles
2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Developed by the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
Mach F, Koskinas KC, van Lennep JER, et al.
Journal:
Eur Heart J

First published: August 29, 2025 DOI: 10.1093/eurheartj/ehaf190
View
- Share
Articles
Triglycerides as Determinants of Global Lipoprotein Derangement: Implications for Cardiovascular Prevention
Amigo N, Torne P, Nordestgaard L, et al.
Journal:
Int J Mol Sci

First published: August 26, 2025 DOI: 10.3390/ijms26178284
View
- Share
Articles
Tackling cardiovascular disease in the Asia-Pacific region: a new Lancet Commission
Lam CSP, Cader FA, Chew NWS, et al.
Journal:
Lancet

First published: August 25, 2025 DOI: 10.1016/S0140-6736(25)01494-1
View
- Share
Articles
Effect of PCSK9 Inhibition With Alirocumab in Patients With Probable Familial Hypercholesterolemia or Type III Hyperlipoproteinemia: Results From the ODYSSEY OUTCOMES Trial
Geba GP, Mohammadi KA, Damask A, et al.
Journal:
J Am Heart Assoc

First published: August 22, 2025 DOI: 10.1161/JAHA.124.041190
View
- Share
Articles
Pharmacotherapy of cardiovascular diseases from herbs and pills to nucleic acids
Landmesser U, Thum T, Tokgözoğlu L, et al.
Journal:
Eur Heart J

First published: August 21, 2025 DOI: 10.1093/eurheartj/ehaf520
View
- Share
Articles
Cost-Effectiveness of Bempedoic Acid in High Cardiovascular Risk Patients with Statin Intolerance: An Analysis of the CLEAR Outcomes Trial
Nicholls SJ, Ray KK, Lincoff AM, et al.
Journal:
Am J Cardiovasc Drugs

First published: August 20, 2025 DOI: 10.1007/s40256-025-00753-w
View
- Share
Articles
Lp(a) testing for the primary prevention of cardiovascular disease in high-income countries: a cost-effectiveness analysis
Morton J, Kronenberg F, Daccord M, et al.
Journal:
Atherosclerosis

First published: August 19, 2025
View
- Share
Articles
Effects of purified eicosapentaenoic acid versus mixed eicosapentaenoic/docosahexaenoic acid pharmacotherapies on coronary plaque volume: network meta-analysis of prospective coronary imaging trials
Sheppard JP, Lakshmanan S, Palatnic L, et al.
Journal:
Acta Cardiol

First published: August 12, 2025 DOI: 10.1080/00015385.2025.2538404
View
- Share
Articles
Low-density lipoprotein cholesterol and cardiovascular risk in the absence of calcifications on computed tomography: the Western Denmark Heart Registry
Andersen MH, Jensen JM, Kanstrup H, et al.
Journal:
Eur Heart J

First published: August 9, 2025 DOI: 10.1093/eurheartj/ehaf497
View
- Share
Articles
Optimizing PCSK9 inhibitor therapy: Understanding and managing suboptimal LDL-C response in clinical practice
Di Girolamo FG, Pellin L, Roni C, et al.
Journal:
Eur J Intern Med

First published: August 8, 2025 DOI: 10.1016/j.ejim.2025.106442
View
- Share

1 2 3 … 10

Collection 5 (Sep 2024 - Aug 2025) Articles

Articles

Determinants of lack of atherosclerosis progression in adult patients with elevated lipoprotein (a): results from the STAR-Lp(a) study

Sosnowska B, Bytyci I, Lewek J, et al.

Articles

Inclisiran-based treatment strategy in hypercholesterolaemia: the VICTORION-Difference trial

Landmesser U, Laufs U, Schatz U, et al.

Articles

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Developed by the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)

Mach F, Koskinas KC, van Lennep JER, et al.

Articles

Triglycerides as Determinants of Global Lipoprotein Derangement: Implications for Cardiovascular Prevention

Amigo N, Torne P, Nordestgaard L, et al.

Articles

Tackling cardiovascular disease in the Asia-Pacific region: a new Lancet Commission

Lam CSP, Cader FA, Chew NWS, et al.

Articles

Effect of PCSK9 Inhibition With Alirocumab in Patients With Probable Familial Hypercholesterolemia or Type III Hyperlipoproteinemia: Results From the ODYSSEY OUTCOMES Trial

Geba GP, Mohammadi KA, Damask A, et al.

Articles

Pharmacotherapy of cardiovascular diseases from herbs and pills to nucleic acids

Landmesser U, Thum T, Tokgözoğlu L, et al.

Articles

Cost-Effectiveness of Bempedoic Acid in High Cardiovascular Risk Patients with Statin Intolerance: An Analysis of the CLEAR Outcomes Trial

Nicholls SJ, Ray KK, Lincoff AM, et al.

Articles

Lp(a) testing for the primary prevention of cardiovascular disease in high-income countries: a cost-effectiveness analysis

Morton J, Kronenberg F, Daccord M, et al.

Articles

Effects of purified eicosapentaenoic acid versus mixed eicosapentaenoic/docosahexaenoic acid pharmacotherapies on coronary plaque volume: network meta-analysis of prospective coronary imaging trials

Sheppard JP, Lakshmanan S, Palatnic L, et al.

Articles

Low-density lipoprotein cholesterol and cardiovascular risk in the absence of calcifications on computed tomography: the Western Denmark Heart Registry

Andersen MH, Jensen JM, Kanstrup H, et al.

Articles

Optimizing PCSK9 inhibitor therapy: Understanding and managing suboptimal LDL-C response in clinical practice

Di Girolamo FG, Pellin L, Roni C, et al.

Articles

Determinants of lack of atherosclerosis progression in adult patients with elevated lipoprotein (a): results from the STAR-Lp(a) study

Sosnowska B, Bytyci I, Lewek J, et al.

Share

Articles

Inclisiran-based treatment strategy in hypercholesterolaemia: the VICTORION-Difference trial

Landmesser U, Laufs U, Schatz U, et al.

Share

Articles

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Developed by the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)

Mach F, Koskinas KC, van Lennep JER, et al.

Share

Articles

Triglycerides as Determinants of Global Lipoprotein Derangement: Implications for Cardiovascular Prevention

Amigo N, Torne P, Nordestgaard L, et al.

Share

Articles

Tackling cardiovascular disease in the Asia-Pacific region: a new Lancet Commission

Lam CSP, Cader FA, Chew NWS, et al.

Share

Articles

Effect of PCSK9 Inhibition With Alirocumab in Patients With Probable Familial Hypercholesterolemia or Type III Hyperlipoproteinemia: Results From the ODYSSEY OUTCOMES Trial

Geba GP, Mohammadi KA, Damask A, et al.

Share

Articles

Pharmacotherapy of cardiovascular diseases from herbs and pills to nucleic acids

Landmesser U, Thum T, Tokgözoğlu L, et al.

Share

Articles

Cost-Effectiveness of Bempedoic Acid in High Cardiovascular Risk Patients with Statin Intolerance: An Analysis of the CLEAR Outcomes Trial

Nicholls SJ, Ray KK, Lincoff AM, et al.

Share

Articles

Lp(a) testing for the primary prevention of cardiovascular disease in high-income countries: a cost-effectiveness analysis

Morton J, Kronenberg F, Daccord M, et al.

Share

Articles

Effects of purified eicosapentaenoic acid versus mixed eicosapentaenoic/docosahexaenoic acid pharmacotherapies on coronary plaque volume: network meta-analysis of prospective coronary imaging trials

Sheppard JP, Lakshmanan S, Palatnic L, et al.

Share

Articles

Low-density lipoprotein cholesterol and cardiovascular risk in the absence of calcifications on computed tomography: the Western Denmark Heart Registry

Andersen MH, Jensen JM, Kanstrup H, et al.

Share

Articles

Optimizing PCSK9 inhibitor therapy: Understanding and managing suboptimal LDL-C response in clinical practice

Di Girolamo FG, Pellin L, Roni C, et al.

Share